Common Stock
- Symbol
- VBIO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Valion Bio, Inc.
VBIONASDAQEQUITYCurrent
Other Events
Item 8.01. Other Matters. On October 21, 2026, Valion Bio, Inc. (the “Company”) issued a press release regarding the Company's new interim chief executive officer, Dean Zikria's first thirty days' assessment. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.
Press release in this filing
Valion Bio’s New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value →Company context
We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are otherwise generally applicable to public companies. As a result:
Current securities
Historical securities (1)
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsNov 2, 2026
- Other EventsOct 29, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 27, 2026
- Other EventsOct 26, 2026
- 424B3 filingOct 21, 2026
Registered securities in this filing
Valion Bio, Inc. · 8-K · Filed 2026-10-22
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Matters.
On October 21, 2026, Valion Bio, Inc. (the “Company”) issued a press release regarding the Company's new interim chief executive officer, Dean Zikria's first thirty days' assessment.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.